Allianz Asset Management GmbH Sells 91,978 Shares of Hologic, Inc. (NASDAQ:HOLX)

Allianz Asset Management GmbH trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 20.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 367,785 shares of the medical equipment provider’s stock after selling 91,978 shares during the quarter. Allianz Asset Management GmbH owned about 0.16% of Hologic worth $26,514,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in HOLX. Capital Investment Counsel Inc grew its holdings in shares of Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider’s stock worth $413,000 after purchasing an additional 200 shares in the last quarter. Handelsbanken Fonder AB grew its stake in Hologic by 8.2% in the 4th quarter. Handelsbanken Fonder AB now owns 214,233 shares of the medical equipment provider’s stock worth $15,444,000 after buying an additional 16,262 shares in the last quarter. Private Advisor Group LLC grew its stake in Hologic by 7.7% in the 4th quarter. Private Advisor Group LLC now owns 17,931 shares of the medical equipment provider’s stock worth $1,293,000 after buying an additional 1,278 shares in the last quarter. Global Retirement Partners LLC increased its holdings in shares of Hologic by 15.5% in the 4th quarter. Global Retirement Partners LLC now owns 2,175 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 292 shares during the last quarter. Finally, Venturi Wealth Management LLC raised its position in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.88% of the company’s stock.

Hologic Price Performance

Shares of Hologic stock opened at $65.01 on Tuesday. The company’s fifty day simple moving average is $69.76 and its two-hundred day simple moving average is $76.41. Hologic, Inc. has a 12-month low of $62.69 and a 12-month high of $84.67. The firm has a market cap of $14.59 billion, a PE ratio of 20.51, a price-to-earnings-growth ratio of 2.14 and a beta of 0.98. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on HOLX shares. Stephens reiterated an “overweight” rating and issued a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. UBS Group increased their price objective on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Evercore ISI reduced their price target on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research report on Thursday, February 6th. Finally, Royal Bank of Canada decreased their price target on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Ten investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.